Last reviewed · How we verify
Stresson — Competitive Intelligence Brief
phase 2
bunitrolol
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Stresson (BUNITROLOL). Bunitrolol is a beta-adrenergic receptor blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Stresson TARGET | BUNITROLOL | phase 2 | bunitrolol |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (bunitrolol class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Stresson CI watch — RSS
- Stresson CI watch — Atom
- Stresson CI watch — JSON
- Stresson alone — RSS
- Whole bunitrolol class — RSS
Cite this brief
Drug Landscape (2026). Stresson — Competitive Intelligence Brief. https://druglandscape.com/ci/bunitrolol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing